Get started
Work

Abstract OT3-02-07: PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)

Year: 2019
Type: conference-abstract
DOI: 10.1158/1538-7445.sabcs18-ot3-02-07
Authors: O Metzger, S Mandrekar, S Loibl, C Mundhenke, S Seiler, P Valagussa, E Lim, D Tripathy, EP Winer, C Huang, L Carey, P Francis, K Miller, MP Goetz, A Prat, S Loi, I Krop, L Gianni, S Delalogue, I Vaz-Luis, T Dockter, J Lanzillotti, E Ciruelos, AM DeMichele
Institutions: University of North Carolina at Chapel Hill, Mayo Clinic, Fondazione Michelangelo, University Hospital Schleswig-Holstein, Hospital Clínic de Barcelona, Dana-Farber Cancer Institute, New York University
Language: English
Field: Medicine
Open Access status: closed
OpenAlex ID: W4241592522
Cites:
Cited by: 15
Related to: 10